Synageva BioPharma Corp. (NASDAQ: GEVA)

 
Press Releases
  Date Title View
Apr 29, 2015
LEXINGTON, Mass., April 29, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today reported first quarter 2015 financial results and provided other business updates.  "This is an exciting time for Synageva as Kanuma moves closer toward patients who ...
PDF
Mar 30, 2015
LEXINGTON, Mass., March 30, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today the submission to the Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) in Mexico for Kanuma as a treatment for patients with lysos...
PDF
Feb 27, 2015
LEXINGTON, Mass., Feb. 27, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, joins the National Organization for Rare Disorders™ (NORD™), the European Organisation for Rare Diseases™ (EURORDIS™), The Global Genes Project͐...
PDF
Feb 26, 2015
LEXINGTON, Mass., Feb. 26, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today reported 2014 full year financial results and provided 2015 goals, other key objectives, and financial guidance.  Synageva's management team will host a conference call today ...
PDF
Feb 25, 2015
LEXINGTON, Mass., Feb. 25, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, announced today its presentation at the upcoming Cowen and Company 35th Annual Health Care Conference in Boston, MA. Sanj K. Patel, President and Chief Executive Off...
PDF
Feb 23, 2015
LEXINGTON, Mass., Feb. 23, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Kanuma™ (sebelipase alfa) for the treatmen...
PDF
Feb 19, 2015
LEXINGTON, Mass., Feb. 19, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (Synageva) (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, will report 2014 fourth quarter and full year financial results after the NASDAQ Market closes on Thursday, February 26, 2015.  Synageva management will conduct a conferen...
PDF
Feb 18, 2015
LEXINGTON, Mass., Feb. 18, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that the European Patent Office issued European Patent No. EP2613798 B1 relating to the treatment of lysosomal acid lipase deficiency (LAL Deficiency).  This patent ...
PDF
Feb 11, 2015
LEXINGTON, Mass., Feb. 11, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that data related to the company's programs will be the subject of three oral presentations and one poster presentation at the WORLDSymposium™ conference, Febr...
PDF
Jan 26, 2015
LEXINGTON, Mass., Jan. 26, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today dosing with SBC-103 in patients with mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) has begun as part of a Phase 1/2 study.  In addition,...
PDF
1
...
NextLast